SF3B1, EGR2, and BIRC3 mutated CLL subclones were stable during the development of clinical zanu resistance, while BTK Cys481 mutation (a secondary drug resistance mechanism), evolved during zanu treatment with clonal expansion due to positive clone selection [49]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.